Ependymoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Video
• Funding
• Clinical Trials
• Forums

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors or Meningiomas Expressing SST2A
Conditions:   High Grade Glioma;   Meningioma;   Embryonal Tumor;   Medulloblastoma;   Anaplastic Ependymoma;   Recurrent Diffuse Intrinsic Pontine Glioma;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Primary Central Nervous System Neoplasm;   Refractory Dif fuse Intrinsic Pontine Glioma;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Primary Central Nervous System Neoplasm Intervention:   Drug: LUTATHERA® (Lutetium Lu 177 dotatate) Sponsors:   Ralph Salloum;   Children's Hospital Medical Center, Cincinnati Not yet recrui...
Source: ClinicalTrials.gov - March 14, 2022 Category: Research Source Type: clinical trials